In a patient with blood urea nitrogen 9.9 mmol/L, creatinine 120 µmol/L, and eGFR 59 mL/min, what medication should be given and is sodium bicarbonate 650 mg twice daily appropriate?

Management of CKD Stage 3a with Metabolic Acidosis

In a patient with eGFR 59 mL/min (CKD stage 3a), BUN 9.9 mmol/L, and creatinine 120 µmol/L, sodium bicarbonate 650 mg twice daily is appropriate and should be initiated to slow CKD progression, though the dose may need titration upward based on serum bicarbonate levels.

Rationale for Sodium Bicarbonate Therapy

• Sodium bicarbonate preserves kidney function by slowing the rate of eGFR decline in patients with CKD and metabolic acidosis, even when eGFR is relatively preserved (mean 75 mL/min in landmark trials). 1

• The proposed dose of 650 mg twice daily (total 1,300 mg/day) is a reasonable starting point, though this represents approximately 15.5 mEq/day—substantially lower than the 36 mEq/day (3,000 mg/day) used in most efficacy trials. 1

• Optimal dosing typically ranges from 1,000 mg three times daily (3,000 mg/day total), which can be titrated based on serum bicarbonate levels measured at 3 months; target serum bicarbonate should be ≥22 mmol/L. 2

Key Monitoring Parameters

• Measure serum bicarbonate, potassium, and blood pressure within 2–4 weeks of initiating therapy to assess response and detect adverse effects. 3

• Check serum bicarbonate at 3 months; if still <22 mmol/L, increase the dose to 1,000 mg three times daily (maximum recommended). 2

• Monitor blood pressure closely, though meta-analysis demonstrates that sodium bicarbonate does not significantly increase systolic BP or antihypertensive medication requirements in CKD patients. 4

Expected Benefits at This Stage of CKD

• At eGFR 59 mL/min (CKD stage 3a), sodium bicarbonate slows the rate of kidney function decline when used as an adjunct to blood pressure control and RAAS blockade. 1

• The protective effect is mediated through correction of acidosis-induced intrarenal injury, though urinary markers of the renin-angiotensin system may not show immediate improvement even after 4 weeks of therapy. 5

• Cardiovascular and mortality benefits remain uncertain in this population; the BiCARB trial showed no improvement in physical function, quality of life, or time to dialysis in older adults with more advanced CKD (stage 4–5), though that trial achieved only modest increments in serum bicarbonate. 2

Concurrent Medication Management

• Continue or optimize ACE inhibitor or ARB therapy even as bicarbonate is initiated; RAAS blockade provides independent cardio- and nephroprotection at eGFR 59 mL/min and should not be discontinued. 3

• Avoid dual RAAS blockade (combining ACE inhibitor with ARB), as this markedly increases hyperkalemia and AKI risk without added benefit. 3

• If blood pressure remains uncontrolled, add a dihydropyridine calcium-channel blocker (e.g., amlodipine 5–10 mg daily), which requires no renal dose adjustment. 3

• Consider initiating an SGLT2 inhibitor (e.g., dapagliflozin 10 mg daily) if the patient has diabetes, heart failure, or significant albuminuria (ACR ≥200 mg/g), as these agents reduce progression to kidney failure even at eGFR 20–45 mL/min. 3

Dosing Guidance from FDA Labeling

• Each tablet contains 650 mg (10 grains) of sodium bicarbonate, which functions as an antacid when used for that indication. 6

• For antacid use, maximum daily dose is 12 tablets (7,800 mg) in adults ≥60 years and 24 tablets in younger adults, though these limits apply to acute antacid use rather than chronic CKD management. 6

• Dissolve tablets completely in water before drinking to ensure absorption and tolerability. 6

Critical Pitfalls to Avoid

• Do not withhold sodium bicarbonate due to concerns about sodium load or blood pressure; evidence shows no significant adverse effect on BP when used for CKD-related acidosis. 4

• Do not use thiazide diuretics if eGFR falls below 30 mL/min, as they become ineffective; loop diuretics (furosemide) remain effective at lower GFR levels. 7, 3

• Do not discontinue RAAS blockade if creatinine rises modestly (≤30%) after initiating bicarbonate or adjusting volume status; this reflects benign hemodynamic changes linked to long-term cardioprotection. 3

• Refer to nephrology when eGFR declines toward 30 mL/min to ensure timely co-management and planning for potential progression. 3